Merck Strengthens Executive Board
Merck Strengthens Executive Board
PR57943
DARMSTADT, Germany, Sep. 19 /PRN=KYODO JBN/ --
Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive
Board
Belen Garijo appointed new member of the Executive Board
Changes effective from January 1, 2015
Merck today announced that the Board of Partners has promoted Stefan
Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive
Board. Concurrently, Belen Garijo (54) was appointed to the Executive Board to
take over leadership for the Pharma business. The management changes will
become effective as of January 1, 2015.
(Photo: http://photos.prnewswire.com/prnh/20140924/706485-a )
(Photo: http://photos.prnewswire.com/prnh/20140924/706485-b )
Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chairman
of the Executive Board. Both will share strategic management functions and will
represent the company with politicians and international organizations.
As a member of the Executive Board, Garijo, currently CEO of Merck's
biopharmaceutical division Merck Serono, will take on responsibility for the
whole Pharma business. Besides Merck Serono, this includes Consumer Health,
Allergy and Biosimilars.
"With today's management decisions we strengthen Merck's leadership team
and prepare the ground for continuity to reach our ambitious growth targets
until the year 2018 and beyond," said Johannes Baillou, Chairman of the Board
of Partners of E. Merck KG. "Stefan Oschmann who has successfully reorganized
our pharma businesses over the past years will familiarize himself with
Group-wide functions and will increasingly assume external responsibilities for
the company. Belen Garijo has many years of experience in the pharma industry,
has proven that she can further develop our business organization and in her
future role will provide a significant contribution to ensure the sustainable
success of our pharma businesses."
Note to editors
You find pictures and CVs here.
All Merck Press Releases are distributed by e-mail at the same time they
become available on the Merck Website. Please go to
http://www.merckgroup.com/subscribe to register online, change your selection
or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech
products in the pharmaceutical and chemical sectors. With its four divisions
Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck
generated total revenues of EURO 11.1 billion in 2013. Around 39,000 Merck
employees work in 66 countries to improve the quality of life for patients, to
further the success of our customers and to help meet global challenges. Merck
is the world's oldest pharmaceutical and chemical company - since 1668, the
company has stood for innovation, business success and responsible
entrepreneurship. Holding an approximately 70% interest, the founding family
remains the majority owner of the company to this day. Merck, Darmstadt,
Germany is holding the global rights to the Merck name and brand. The only
exceptions are Canada and the United States, where the company is known as EMD.
SOURCE: Merck
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。